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41. The myocardial protective effect of dexmedeto-
midine in high risk patients undergoing aortic
vascular surgery
R. Soliman
Cairo University, Giza, Egypt
Dexmedetomidine provides perioperative cardiac pro-
tection in high risk patients assessment the effect of dex-
medetomidine in high risk patients undergoing aortic
vascular surgery. Arandomized study included 150
patients classified into two groups(n = 75). Group D:
The patients received a loading dose of 1 lg/kg dexme-
detomidine over 15 min before induction and maintained
as an infusion of 0.3 lg/kg/hr to the end of the procedure.
Group C: The patients received an equal volume of nor-
malsaline. The dexmedetomidine decreased heart rate
and minimized the changes in blood pressure compared
to control group (p < 0.05). Also, it decreased the inci-
dence of myocardial is chemia reflected by troponin I
level and ECG changes(p < 0.05). Dexmedetomidine
decreased the requirement for nitroglycerine and norepi-
nephrine compared to control group (p < 0.05). The inci-
dence of hypotension and bradycardia were
significantly higher with dexmedetomidine (p < 0.05).
The dexmedetomidine is safe and effective in patients
undergoing aortic vascular surgery. It decreases the
changes in heart rate and blood pressure during the pro-
cedures. It provide scardiac protection in high risk
patients reflected by decreasing the incidence of myocar-
dial ischemia and serum level of troponin. The main side
effects of dexmedetomidine were hypotension and
bradycardia.
http://dx.doi:10.1016/j.jsha.2016.04.042
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42. The effect of ticagrelor on coronary blood after
primary PCI when compared with clopidogril
W. Kadro
The Golden Center for Cardiovascular Research,
Damascus, Syrian Arab Republic
Primary PCI (PPCI) has been established as the best
treatment for acute MI when it is used appropriately. It is
known to give better TIMI III flow and better frame count
when compared with thrombolytics. Loading with P2Y12
inhibitors in the ER prior to primary PCI is an important
step in antiplatelet therapy for acute myocardial infarction.
In this studyWe report the effect of loadingwith two differ-
ent P2Y12 inhibitors (ticagrelor and clopidogril) on theTIMI
frame count in the culprit artery after successful PPCI. Tica-
grelor may affect coronary microcirculation and coronary
blood flow through faster and stronger platelet inhibition.
We randomized 44 patient who presented to our center
with acute MI into two groups. The first group received a
loading with 180mg of ticagrelor and the second group
received a loading with 600 mg of clopidogril. The mean
door to balloon time was 98 ± 12 min. All patients in both
groups received a loading with 162 mg of aspirin. GP IIb/
IIIa inhibitors were used in all cases together with adjusted
dose heparin. Stent usage was 100%. No thrombectomy or
thrombus aspiration device was used in any of these cases.
TIMI III flow after stenting was achieved in all culprit
arteries. Then we calculated the TIMI frame count in the
culprit artery after successful primary PCI. The mean cor-
rected TIMI frame count in the culprit artery post PCI was
18.34 ± 3.16 frames in group 1 (Ticagrelor group) and
28.73 ± 3.92 in group 2 (clopidogril group) (p = 0.02). Load-
ingwith ticagrelor gives faster flow after successful primary
PCI in the culprit artery of acute MI when compared with
clopidogril. This can be explained by the fact that ticagrelor
therapy give faster P2Y12 inhibition thus faster antiplatelet
therapy causing less platelet aggregation resulting in less
distal embolization and reduced production of inflamma-
tory mediators and adhesion molecules which may result
in faster restoration of normal endothelial function. This
finding may partially explain the mortality benefit of tica-
grelor in a previousACS study. A larger prospective rando-
mized study is needed to confirm this finding.
http://dx.doi:10.1016/j.jsha.2016.04.043
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43. Calmodulin regulating calcium sensitivity of Na
channels
R. Vegiraju
University of Texas at Austin, Austin, USA
By extrapolating information from existing research and
observing previous assumptions regarding the structure of
the Na Channel, this experiment was conducted under the
hypothesis that the Na Channel is in part regulated by the
calmodulin protein, as a result proving calcium sensitivity
of the Na Channel. Furthermore, we assume that there is
a one to one stoichiometry between the Na Channel and
the Calmodulin. There has been extensive research into
the functionality and structure of sodium ion channels
(Na channels), as several diseases are associated with the
lack of regulation of sodium ions, that is caused by the dis-
function of theseNa channels.However, one highly contro-
versial matter in the field is the importance of the protein
calmodulin (CaM) and calcium inNachannel function.Cal-
modulin is a protein that is well known for its role as a cal-
cium binding messenger protein, and that association is
believed to play an indirect role in regulating the Na chan-
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